Core Viewpoint - Citius Oncology, Inc. has successfully closed a registered direct offering and concurrent private placement, raising approximately $9.0 million through the sale of 5,142,858 shares of common stock and warrants [1][2]. Group 1: Offering Details - The effective offering price for each share of common stock and accompanying warrant was $1.75, with warrants having an exercise price of $1.84 per share [1]. - The warrants will be exercisable six months from the date of issuance and will expire on the five and one-half year anniversary from the date of issuance [1]. - Maxim Group LLC acted as the sole placement agent for the offering, which was conducted under a registration statement filed with the SEC [3]. Group 2: Company Overview - Citius Oncology is focused on developing and commercializing novel targeted oncology therapies, with its primary asset, LYMPHIR, approved by the FDA for treating relapsed or refractory CTCL [5]. - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies [5]. - Citius Pharmaceuticals, the parent company, also has a late-stage pipeline including Mino-Lok® and CITI-002 (Halo-Lido) [6].